Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Laboratory Corporation of America Holdings Reaffirms FY 2013 Revenue Guidance; Narrows FY 2013 EPS Guidance To A Range In Line With Analysts' Estimates


Friday, 19 Jul 2013 06:55am EDT 

Laboratory Corporation of America Holdings updated its fiscal 2013 guidance and expects revenue growth in the range of approximately 2.0% to 3.0%; Adjusted EPS Excluding Amortization of $6.90 to $7.10, which includes a negative impact of approximately $0.35 due to Medicare payment reductions and excludes the impact of any share repurchase activity after June 30, 2013; operating cash flow of approximately $825 million to $850 million; and capital expenditures of approximately $200 million to $220 million. The Company's capital expenditure guidance is higher than historical levels due to near-term investments in facility consolidation and the replacement of a major testing platform. The Company reported revenue of $5.671 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $5.788 billion and EPS of $7.09 for fiscal 2013. 

Company Quote

108.25
0.56 +0.52%
26 Dec 2014